Recent Activities by Topic

  • FAQ: What is the role of emerging targeted therapies in AML? - N. Daver, MD - Posted 06/06
    text
  • VIDEO FAQ: What has been found to be the median time to best response with enasidenib? - H. Carraway, MD (1:22) - Posted 05/23
    video
  • VIDEO: Are IDH2 Inhibitors Right for Your AML Patient? - H. Carraway, MD  (27:10) - Posted 05/15
    CE video
  • FAQ: What is standard of care for patients unfit for intensive induction chemotherapy, and what is under investigation? - N. Daver, MD - Posted 05/09
    text
  • VIDEO FAQ: Therapy-related AML: Its relationship to de novo AML and how it impacts prognosis and treatment - J. Lancet, MD (5:10) - Posted 02/28
    video
  • Additional activities...
  • VIDEO FAQ: Do I need to re-test patients at relapse who had an IDH mutation at diagnosis? - H. Carraway, MD (1:07) - Posted 05/02
    video
  • CASE: 53-year-old woman presenting with severe fatigue and bruising - J. Khoury, MD (3:57) - Posted 03/21
    audio
  • VIDEO FAQ: The hematopathologist's role in the diagnosis of AML - J. Khoury, MD (7:10) - Posted 12/26
    video
  • FAQ: Is molecular testing standard/routine for patients diagnosed with AML in the community setting? - B. Druker, MD - Posted 05/31
    text
  • Additional activities...

Supporters

MediCom Worldwide, Inc. would like to recognize and thank the following companies for their educational support of Managing AML.com in 2018

  • Agios Pharmaceuticals, Inc.
  • Celgene Corporation
  • Daiichi Sankyo, Inc.
  • Helsinn

MediCom Oncology Links

Please visit these other members of the MediCom Oncology family of sites.

Managing MDS Managing Myeloma The Practical Oncologist
Managing Hodgkin Lymphoma Partners in Pancreatic Cancer Emerging Solutions in Pain